Patents by Inventor Kouji Matsushima

Kouji Matsushima has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210220320
    Abstract: Disclosed is a novel means that is effective for analgesia or sedation. The analgesic or sedative agent of the present invention comprises, an active component, disulfiram, a metal complex of diethyldithiocarbamate, a disulfide capable of generating diethyldithiocarbamate in the body, a pharmaceutically acceptable salt of any of these compounds, or a solvate of any of these compounds or salts thereof. Disulfiram and the above-described metal complex are known to have anticancer and anti-inflammatory effects. The agent of the present invention can exert multiple therapeutic benefits such as anticancer, anti-inflammatory, analgesic, and sedative effects, in cancer patients.
    Type: Application
    Filed: January 31, 2019
    Publication date: July 22, 2021
    Applicant: THE UNIVERSITY OF TOKYO
    Inventors: Yuya TERASHIMA, Etsuko TODA, Kouji MATSUSHIMA
  • Publication number: 20200407408
    Abstract: Disclosed are a novel therapeutic means effective and practical against cancer, and a novel substance useful as such a therapeutic means. Provided are novel peptides derived from a partial region of HMGN1, HMGN2, HMGN4 or HMGN5, and anti-cancer agents and anti-cancer effect enhancers containing the peptide as an active ingredient. The peptide of the present invention has an anti-tumor effect even independently, and exerts a remarkably excellent anti-tumor effect particularly when used in combination with an immune checkpoint regulator, or an anti-CD4 antibody or antigen-binding fragment thereof.
    Type: Application
    Filed: March 7, 2019
    Publication date: December 31, 2020
    Applicants: The University of Tokyo, ONO PHARMACEUTICAL CO., LTD., TOKYO UNIVERSITY OF SCIENCE FOUNDATION
    Inventors: Kouji MATSUSHIMA, Satoshi UEHA, Shungo DESHIMARU, Chang-Yu CHEN, Shoji YOKOCHI, Yoshiro ISHIWATA, Shiro SHIBAYAMA
  • Patent number: 10746726
    Abstract: Means that enables monitoring of an anticancer effect of an anti-CD4 antibody or an anticancer drug targeting an immune checkpoint is disclosed. The method for testing a therapeutic effect of a cancer therapy of the present invention is a method for testing a therapeutic effect of an anticancer drug comprising as an effective ingredient an anti-CD4 antibody or an anticancer drug targeting an immune checkpoint, which method comprises investigation of expression of (1) at least one immune checkpoint receptor, (2) CD8, and (3) at least one cell surface molecule selected from the group consisting of CD44 and CD45RO, on T cells using a sample derived from a patient who received the anticancer drug. Induction of a T cell population which is positive for the immune checkpoint molecule (1) and positive for CD8, and which shows high expression of CD44 and/or high expression of CD45RO, indicates that said anticancer drug is producing a therapeutic effect in said patient.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: August 18, 2020
    Assignees: THE UNIVERSITY OF TOKYO, IDAC THERANOSTICS, INC.
    Inventors: Kouji Matsushima, Satoshi Ueha, Satoru Ito, Shoji Yokochi, Yoshiro Ishiwata
  • Publication number: 20200253896
    Abstract: An agent according to the present invention comprises as an effective component any of (1) disulfiram, diethyldithiocarbamate, or a metal complex of diethyldithiocarbamate; (2) a pharmaceutically acceptable salt of (1); or (3) a solvate of (1) or (2), and is used for inhibition of interaction between CR2B or CCR5 and FROUNT protein, inhibition of macrophages, control of cells constituting a cancer microenvironment or inflammatory microenvironment, or enhancement of anticancer activity of an anticancer drug. It is also possible to provide a compound with a reduced side effect and an increased pharmacological effect by identifying a disulfiram derivative having a lower aldehyde dehydrogenase-inhibiting activity and a higher FROUNT-inhibiting activity among derivatives prepared by structural modification of disulfiram.
    Type: Application
    Filed: February 20, 2020
    Publication date: August 13, 2020
    Applicant: The University of Tokyo
    Inventors: Yuya TERASHIMA, Kouji MATSUSHIMA, Etsuko TODA, Hiroaki TERASAWA, Sosuke YOSHINAGA
  • Patent number: 10738352
    Abstract: The present invention relates to a method of analyzing a composition of nucleic acids derived from a single cell using a microplate including a plurality of reaction wells, the microplate having one bead arranged in one reaction well, the one bead having bound thereto a plurality of molecules of single-stranded oligonucleotides, the single-stranded oligonucleotides each having a nucleic acid capture sequence exposed at the 3? end and a barcode sequence on the 5? side of the nucleic acid capture sequence, the barcode sequence including a base sequence that differs from bead to bead.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: August 11, 2020
    Assignee: IDAC THERANOSTICS, INC.
    Inventors: Shin-ichi Hashimoto, Shuichi Kaneko, Kouji Matsushima
  • Patent number: 10722480
    Abstract: An agent according to the present invention comprises as an effective component any of (1) disulfiram, diethyldithiocarbamate, or a metal complex of diethyldithiocarbamate; (2) a pharmaceutically acceptable salt of (1); or (3) a solvate of (1) or (2), and is used for inhibition of interaction between CR2B or CCR5 and FROUNT protein, inhibition of macrophages, control of cells constituting a cancer microenvironment or inflammatory microenvironment, or enhancement of anticancer activity of an anticancer drug. It is also possible to provide a compound with a reduced side effect and an increased pharmacological effect by identifying a disulfiram derivative having a lower aldehyde dehydrogenase-inhibiting activity and a higher FROUNT-inhibiting activity among derivatives prepared by structural modification of disulfiram.
    Type: Grant
    Filed: January 6, 2016
    Date of Patent: July 28, 2020
    Assignee: TOKYO UNIVERSITY OF SCIENCE FOUNDATION
    Inventors: Yuya Terashima, Kouji Matsushima, Etsuko Toda, Hiroaki Terasawa, Sosuke Yoshinaga
  • Patent number: 10300115
    Abstract: The instant invention provides methods and compositions for modulation of the immune system. Specifically, the present disclosure provides methods and compositions for increasing T cell mediated immune response useful in the treatment of cancer and chronic infection.
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: May 28, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Arya Biragyn, Kouji Matsushima, Dolgor Baatar
  • Publication number: 20190125867
    Abstract: Disclosed is a novel means effective for treatment, metastasis-inhibition, and recurrence-inhibition of human solid cancer. A therapeutic agent for solid cancer according to the present invention comprises as an effective ingredient an anti-CD4 antibody having a high cytotoxic activity, or an anti-CD4 antibody or antigen-binding fragment thereof which antibody or fragment comprises a cytotoxic component bound thereto. Said anti-CD4 antibody is a human-type chimeric antibody, humanized antibody or human antibody against human CD4. The therapeutic agent of the present invention produces still higher effects by combined use with antagonist or agonist against immune checkpoint molecule, small molecule anticancer agents, or the like. The therapeutic agent is also effective in suppressing recurrence and metastasis of solid cancer.
    Type: Application
    Filed: December 27, 2018
    Publication date: May 2, 2019
    Applicants: IDAC THERANOSTICS, INC., THE UNIVERSITY OF TOKYO
    Inventors: Satoru ITO, Shoji YOKOCHI, Kouji MATSUSHIMA, Satoshi UEHA, Yoshiro ISHIWATA
  • Publication number: 20180237860
    Abstract: Novel means that enables prediction of prognosis of a patient with cancer or inflammatory disease is disclosed. In the method for prediction of prognosis of a patient with cancer or inflammatory disease according to the present invention, the expression level of the FROUNT gene in a sample collected from the patient is measured. Since FROUNT is a poor prognostic factor, the lower the expression level of the FROUNT gene is, the better the prognosis in the patient is predicted to be. Or, the expression level of the CC chemokine receptor/ligand gene in a sample collected from the patient is measured. Since the CC chemokine receptor/ligand gene such as CCR2 or CCR5 is a good prognostic factor, the higher the expression level of the CC chemokine receptor/ligand gene is, the better the prognosis in the patient is predicted to be.
    Type: Application
    Filed: January 8, 2016
    Publication date: August 23, 2018
    Applicants: The University of Tokyo, CHIBA PREFECTURE
    Inventors: Yuya TERASHIMA, Kouji MATSUSHIMA, Etsuko TODA, Mikiya OTSUJI, Meiji ITAKURA
  • Patent number: 9895331
    Abstract: An object of the present invention is to provide a preventive and/or therapeutic agent for radiation damage that has a novel mechanism of action and can prevent and alleviate a wide range of symptoms of radiation damage for which no therapeutic measures have been available so far, and moreover, is highly safe to humans. A preventive and/or therapeutic agent for radiation damage comprising a compound represented by the following formula (I) such as 5-aminolevulinic acid (5-ALA) or a salt thereof as an active ingredient can be used to improve the survival rate, improve body weight reduction, and alleviate hematopoietic disorder: (wherein R1 represents a hydrogen atom or an acyl group; and R2 represents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aryl group, or an aralkyl group).
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: February 20, 2018
    Assignees: The University of Tokyo, SBI Pharmaceuticals Co., Ltd.
    Inventors: Tohru Tanaka, Motowo Nakajima, Fuminori Abe, Hidenori Ito, Kiwamu Takahashi, Kouji Matsushima, Satoshi Ueha, Jun Abe
  • Publication number: 20180000755
    Abstract: An agent according to the present invention comprises as an effective component any of (1) disulfiram, diethyldithiocarbamate, or a metal complex of diethyldithiocarbamate; (2) a pharmaceutically acceptable salt of (1); or (3) a solvate of (1) or (2), and is used for inhibition of interaction between CR2B or CCR5 and FROUNT protein, inhibition of macrophages, control of cells constituting a cancer microenvironment or inflammatory microenvironment, or enhancement of anticancer activity of an anticancer drug. It is also possible to provide a compound with a reduced side effect and an increased pharmacological effect by identifying a disulfiram derivative having a lower aldehyde dehydrogenase-inhibiting activity and a higher FROUNT-inhibiting activity among derivatives prepared by structural modification of disulfiram.
    Type: Application
    Filed: January 6, 2016
    Publication date: January 4, 2018
    Applicant: The University of Tokyo
    Inventors: Yuya TERASHIMA, Kouji MATSUSHIMA, Etsuko TODA, Hiroaki TERASAWA, Sosuke YOSHINAGA
  • Publication number: 20170328887
    Abstract: Means that enables monitoring of an anticancer effect of an anti-CD4 antibody or an anticancer drug targeting an immune checkpoint is disclosed. The method for testing a therapeutic effect of a cancer therapy of the present invention is a method for testing a therapeutic effect of an anticancer drug comprising as an effective ingredient an anti-CD4 antibody or an anticancer drug targeting an immune checkpoint, which method comprises investigation of expression of (1) at least one immune checkpoint receptor, (2) CD8, and (3) at least one cell surface molecule selected from the group consisting of CD44 and CD45RO, on T cells using a sample derived from a patient who received the anticancer drug. Induction of a T cell population which is positive for the immune checkpoint molecule (1) and positive for CD8, and which shows high expression of CD44 and/or high expression of CD45RO, indicates that said anticancer drug is producing a therapeutic effect in said patient.
    Type: Application
    Filed: December 2, 2015
    Publication date: November 16, 2017
    Applicants: The University of Tokyo, IDAC Theranostics, Inc.
    Inventors: Kouji MATSUSHIMA, Satoshi UEHA, Satoru ITO, Shoji YOKOCHI, Yoshiro ISHIWATA
  • Publication number: 20170166959
    Abstract: The present invention relates to a method of analyzing a composition of nucleic acids derived from a single cell using a microplate including a plurality of reaction wells, the microplate having one bead arranged in one reaction well, the one bead having bound thereto a plurality of molecules of single-stranded oligonucleotides, the single-stranded oligonucleotides each having a nucleic acid capture sequence exposed at the 3? end and a barcode sequence on the 5? side of the nucleic acid capture sequence, the barcode sequence including a base sequence that differs from bead to bead.
    Type: Application
    Filed: April 7, 2015
    Publication date: June 15, 2017
    Applicant: IDAC THERANOSTICS, INC.
    Inventors: Shin-ichi Hashimoto, Shuichi Kaneko, Kouji Matsushima
  • Publication number: 20170165364
    Abstract: Disclosed is a novel means effective for treatment, metastasis-inhibition, and recurrence-inhibition of human solid cancer. A therapeutic agent for solid cancer according to the present invention comprises as an effective ingredient an anti-CD4 antibody having a high cytotoxic activity, or an anti-CD4 antibody or antigen-binding fragment thereof which antibody or fragment comprises a cytotoxic component bound thereto. Said anti-CD4 antibody is a human-type chimeric antibody, humanized antibody or human antibody against human CD4. The therapeutic agent of the present invention produces still higher effects by combined use with antagonist or agonist against immune checkpoint molecule, small molecule anticancer agents, or the like. The therapeutic agent is also effective in suppressing recurrence and metastasis of solid cancer.
    Type: Application
    Filed: February 9, 2015
    Publication date: June 15, 2017
    Applicants: IDAC THERANOSTICS, INC., THE UNIVERSITY OF TOKYO
    Inventors: Satoru ITO, Shoji YOKOCHI, Kouji MATSUSHIMA, Satoshi UEHA, Yoshiro ISHIWATA
  • Publication number: 20170145099
    Abstract: Disclosed is a means for reducing side effects of an immune checkpoint regulator that is used as an anticancer drug or the like. A side-effect reducing agent according to the present invention comprises as an effective ingredient an anti-CD4 antibody having a high cytotoxic activity, or an anti-CD4 antibody or antigen-binding fragment thereof which antibody or fragment comprises a cytotoxic component bound thereto. The anti-CD4 antibody is a human-type chimeric antibody, humanized antibody or human antibody against human CD4. The immune checkpoint regulator may be, for example, an anti-PD-L1 antibody, an antagonistic anti-CTLA-4 antibody, or an agonistic anti-OX40 antibody.
    Type: Application
    Filed: June 10, 2015
    Publication date: May 25, 2017
    Applicants: IDAC Theranostics, Inc., The University of Tokyo
    Inventors: Satoru ITO, Shoji YOKOCHI, Kouji MATSUSHIMA, Satoshi UEHA, Yoshiro ISHIWATA
  • Publication number: 20170119858
    Abstract: The instant invention provides methods and compositions for modulation of the immune system. Specifically, the present disclosure provides methods and compositions for increasing T cell mediated immune response useful in the treatment of cancer and chronic infection.
    Type: Application
    Filed: January 11, 2017
    Publication date: May 4, 2017
    Inventors: Arya Biragyn, Kouji Matsushima, Dolgor Baatar
  • Patent number: 9605044
    Abstract: The instant invention provides methods and compositions for modulation of the immune system. Specifically, the invention provides methods and compositions for increasing T cell mediated immune response useful in the treatment of cancer and chronic infection.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: March 28, 2017
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Arya Biragyn, Kouji Matsushima, Dolgor Baatar
  • Patent number: 9156912
    Abstract: The object of the invention is to provide an immunological reconstitution promoter or a prophylactic agent for infections for use in allogeneic hematopoietic stem cell transplantation therapy for tumors. The promoter or prophylactic agent enables the amelioration of delayed immune reconstitution or the prevention of infection following transplantation, while maintaining the GVT effect of allogeneic hematopoietic stem cell transplantation. Specifically, in a transplant patient in whom immune reconstitution is delayed, such reconstitution can be promoted by administering, at an early stage following transplantation, a substance capable of depleting CD4+ cells. Early completion of infection management in the patient and improvement in the survival rate are anticipated as a result. In addition, the risk of complications associated with allogeneic hematopoietic stem cell transplantation is reduced, enabling more widespread use of this therapy.
    Type: Grant
    Filed: November 4, 2009
    Date of Patent: October 13, 2015
    Assignee: The University of Tokyo
    Inventors: Kouji Matsushima, Satoshi Ueha, Yusuke Shono
  • Publication number: 20150190356
    Abstract: An object of the present invention is to provide a preventive and/or therapeutic agent for radiation damage that has a novel mechanism of action and can prevent and alleviate a wide range of symptoms of radiation damage for which no therapeutic measures have been available so far, and moreover, is highly safe to humans. A preventive and/or therapeutic agent for radiation damage comprising a compound represented by the following formula (I) such as 5-aminolevulinic acid (5-ALA) or a salt thereof as an active ingredient can be used to improve the survival rate, improve body weight reduction, and alleviate hematopoietic disorder: (wherein R1 represents a hydrogen atom or an acyl group; and R2 represents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aryl group, or an aralkyl group).
    Type: Application
    Filed: July 11, 2013
    Publication date: July 9, 2015
    Applicants: The University of Tokyo, SBI Pharmaceuticals Co., Ltd.
    Inventors: Tohru Tanaka, Motowo Nakajima, Fuminori Abe, Hidenori Ito, Kiwamu Takahashi, Kouji Matsushima, Satoshi Ueha, Jun Abe
  • Patent number: 8946386
    Abstract: Purified immunocytes were analyzed for expression frequencies, and the NKIR gene expressed specifically in natural killer (NK) cells was successfully identified. The NKIR gene encodes a receptor. Agonists and antagonists for the receptor can be identified by using the receptor.
    Type: Grant
    Filed: September 29, 2004
    Date of Patent: February 3, 2015
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Kouji Matsushima, Shinichi Hashimoto, Masayuki Tsuchiya, Yuichi Hirata, Kenji Yoshida, Kazuyuki Ojima